Cross-border play LianBio’s ninth in-licensed therapy comes via Lyra to build out inflammatory pillar 

LianBio’s fifth in-licensing deal since its launch last year adds a third anti-inflammatory from U.S. biotech Lyra to the Perceptive Advisors-backed cross-border company’s pipeline, bringing its assets to nine. 

LianBio, a start-up based in Shanghai and Princeton, N.J. that has therapies spanning cardio-renal, oncology, respiratory, ophthalmic and inflammatory indications, gains exclusive rights to develop and commercialize LYR-210 in mainland China, Hong Kong, Macao, Singapore, South Korea, Taiwan and Thailand. LYR-210, a nasal implant designed to deliver mometasone furoate for up to six months, has completed Phase II testing to treat chronic rhinosinusitis (CRS). ...